The trajectory of copyright's flagship drug presents a interesting case for observers in the medicinal sector. While initially a phenomenal success, creating billions, the intellectual property lapse and the subsequent entry of off-brand versions have considerably changed income. This poses questions about the long-term profitability of related … Read More